Clinuvel Pharmaceuticals Limited Share Price Nasdaq
Stocks
CUVL
US1887691038
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Nasdaq
21:30:00 27/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 6.770 USD | -11.44% |
|
-13.21% | -20.17% |
| 11:44am | Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10 | MT |
| 08-27 | Clinuvel Pharmaceuticals Limited, 2026 Earnings Call, Aug 27, 2026 |
| Market Cap | 463M 333M 286M 268M 245M 462M 31.8B 3.17B 1.24B 16.03B 1.25B 1.22B 53.05B | P/E 2027 * |
14.9x | P/E 2028 * | 9.39x |
|---|---|---|---|---|---|
| Enterprise Value | 186M 134M 115M 107M 98.42M 185M 12.77B 1.27B 498M 6.44B 502M 491M 21.31B | EV / Sales 2027 * |
2.02x | EV / Sales 2028 * | 1.2x |
| Free-Float |
83.79% | Yield 2027 * |
0.63% | Yield 2028 * | 0.82% |
Last Transcript : Clinuvel Pharmaceuticals Limited
| 1 day | -11.44% | ||
| 1 week | -13.21% | ||
| Current month | +4.31% | ||
| 1 month | -3.42% | ||
| 3 months | +3.20% | ||
| 6 months | -10.45% | ||
| Current year | -20.17% |
| 1 week | 6.76 |  | 8.2 |
| 1 month | 6.2 | | 8.2 |
| Current year | 5.98 | | 8.67 |
| 1 year | 5.98 | | 8.92 |
| 3 years | 5.98 | | 13.45 |
| 5 years | 5.98 | | 31.44 |
| 10 years | 3.81 | | 31.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 31/10/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 29/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 28/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 22/09/2019 |
| Chairman | - | 31/12/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -11.44% | -13.21% | - | - | 333M | |
| -0.87% | -2.29% | +37.61% | -2.73% | 80.65B | |
| -4.60% | +7.09% | +468.80% | +27.55% | 57B | |
| -0.90% | +3.51% | -19.91% | -35.69% | 59.9B | |
| +0.76% | +3.53% | +0.08% | +36.18% | 53.35B | |
| -1.04% | -0.95% | +9.58% | +167.22% | 49.29B | |
| +0.19% | +3.34% | +62.44% | -16.23% | 32.73B | |
| -0.30% | +0.41% | +50.57% | +100.03% | 25.89B | |
| -0.09% | +4.98% | +18.59% | +209.35% | 23.9B | |
| +0.56% | +1.03% | +62.43% | +124.64% | 17.07B | |
| Average | -1.20% | +2.48% | +76.69% | +67.81% | 44.42B | |
| Weighted average by Cap. | -0.17% | +2.10% | +84.80% | +46.46% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 92.03M 66.2M 56.83M 53.2M 48.72M 91.77M 6.32B 630M 246M 3.19B 249M 243M 10.55B | 121M 86.96M 74.65M 69.89M 64M 121M 8.31B 828M 324M 4.19B 327M 319M 13.85B |
| Net income | 32.2M 23.16M 19.88M 18.61M 17.04M 32.11M 2.21B 220M 86.17M 1.11B 86.96M 85.08M 3.69B | 45.98M 33.08M 28.39M 26.58M 24.34M 45.85M 3.16B 315M 123M 1.59B 124M 122M 5.27B |
| Net Debt | -277M -199M -171M -160M -147M -276M -19.03B -1.9B -741M -9.59B -748M -732M -31.74B | -317M -228M -196M -183M -168M -316M -21.8B -2.17B -849M -10.99B -857M -839M -36.37B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/08/26 | US$6.770 | -11.44% | 30,794 |
| 26/08/26 | US$7.644 | +0.58% | 1,339 |
| 25/08/26 | US$7.600 | +2.43% | 14,095 |
| 24/08/26 | US$7.420 | -4.87% | 26,659 |
| 20/08/26 | US$7.800 | +9.09% | 26,407 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- CUVL Stock
Select your edition
All financial news and data tailored to specific country editions
